These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16240906)

  • 1. Gastric pH, sevelamer hydrochloride and omeprazole.
    Capitanini A; Lupi A; Osteri F; Petrone I; Del Corso C; Straniti M; Gallieni M; Rossi A
    Clin Nephrol; 2005 Oct; 64(4):320-2. PubMed ID: 16240906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis.
    Hardy P; Sechet A; Hottelart C; Oprisiu R; Abighanem O; Said S; Rasombololona M; Brazier M; Moriniere P; Achard JM; Pruna A; Fournier A
    Artif Organs; 1998 Jul; 22(7):569-73. PubMed ID: 9684693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy.
    Leite LP; Johnston BT; Just RJ; Castell DO
    Am J Gastroenterol; 1996 Aug; 91(8):1527-31. PubMed ID: 8759655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omeprozole therapy in pediatric patients after liver and intestinal transplantation.
    Kaufman SS; Lyden ER; Brown CR; Davis CK; Andersen DA; Olsen KM; Bergman KL; Horslen SP; Sudan DL; Fox IJ; Shaw BW; Langnas AN
    J Pediatr Gastroenterol Nutr; 2002 Feb; 34(2):194-8. PubMed ID: 11840039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
    Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H;
    Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel dosage forms and regimens for sevelamer-based phosphate binders.
    Duggal A; Hanus M; Zhorov E; Dagher R; Plone MA; Goldberg J; Burke SK
    J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study.
    Lai B; Cervelli MJ
    Nephrology (Carlton); 2012 May; 17(4):402-6. PubMed ID: 22329674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient acid exposure increases sevelamer HCl phosphate binding.
    Ross EA; Scott WE; Odukale AA; Alba NA; Batich CD
    J Pharm Sci; 2007 Aug; 96(8):2154-60. PubMed ID: 17506513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
    Wilkes BM; Reiner D; Kern M; Burke S
    Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sevelamer reduces the efficacy of many other drugs.
    Prescrire Int; 2009 Aug; 18(102):164-5. PubMed ID: 19743578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of the efficacy and factors influencing the response of secondary hyperparathyroidism patients on hemodialysis to cinacalcet].
    Segura Torres P; Borrego Utiel FJ; Sánchez Perales MC; García Cortés MJ; Biechy Baldán MM; Pérez Bañasco V
    Nefrologia; 2010; 30(4):443-51. PubMed ID: 20651886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibition of gastric secretion by omeprazole and efficacy of calcium carbonate in the control of hyperphosphatemia in patients on maintenance hemodialysis].
    Séchet A; Abighanem O; Said S; Rasombololona M; Morinière P; Brazier M; Fournier A
    Nephrologie; 1999; 20(4):213-6. PubMed ID: 10480154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects.
    Röhss K; Wilder-Smith C; Kilhamn J; Fjellman M; Lind T
    Int J Clin Pharmacol Ther; 2007 Jun; 45(6):345-54. PubMed ID: 17595892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
    Suñer M; Guerrero A; Montes R; Rivera M; Ruiz A; Martínez-García M; Pérez-Valdivia MA; Mateos J
    Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage.
    Oka Y; Miyazaki M; Takatsu S; Kunitomo K; Uno F; Maruyama M; Matsuda H
    Ther Apher Dial; 2007 Apr; 11(2):107-13. PubMed ID: 17381531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.
    Mahdavi H; Kuizon BD; Gales B; Wang HJ; Elashoff RM; Salusky IB
    Pediatr Nephrol; 2003 Dec; 18(12):1260-4. PubMed ID: 14586677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment.
    Coppolino G; Lucisano S; Rivoli L; Fuiano G; Villari A; Villari I; Leonello G; Lacquaniti A; Santoro D; Buemi M
    Ther Apher Dial; 2015 Oct; 19(5):471-6. PubMed ID: 25866250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers.
    Calafatti SA; Ortiz RA; Deguer M; Martinez M; Pedrazzoli J
    Br J Clin Pharmacol; 2001 Aug; 52(2):205-9. PubMed ID: 11488780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children.
    Kato S; Takeyama J; Ebina K; Naganuma H
    Pediatrics; 1997 Jul; 100(1):E3. PubMed ID: 9200377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.